PODESTA GROUP, INC. for AMGEN
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare Part B reimbursement and coverage of dialysis products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Budget/Appropriations BUD
Prescription Drug User Fee Act reauthorization. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 5973/S. 2375, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2013. H. J. Res. 117, Continuing Appropriations Resolution, 2013. H.R. 6433, FDA User Fee Corrections Act of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
Health Issues HCR
Prescription Drug User Fee Act reauthorization. Biosimilar products. H.R. 5651, Food and Drug Administration Reform Act of 2012. S. 3187, Food and Drug Administration Safety and Innovation Act. H.R. 6433, FDA User Fee Corrections Act of 2012.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| OSCAR RAMIREZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.